Oncology Pharma Inc - ONPH stock

Click the button to add ONPH to the list of your stock picks.

Pick this!

Recently Updated Wikis

• ZAIRF
  Zinc8 Energy Solutions Inc
• JUVAF
  Juva Life Inc
• GMGMF
  Graphene MFG Group Ltd
• CYDY
  Cytodyn Inc
• CBULF
  Gratomic Inc
• GTII
  Global Tech Industries
• PLTXF
  Plantx Life Inc
• NEXNF
  NEXE Innovations Inc
• ZPTAF
  Surge Energy Inc.
• VLTLF
  Volt Lithium Corp

OTC Symbol: ONPH

Company Profile

Oncology Pharma Inc. [OTCPK: ONPH] is a California-based oncology company that licenses, develops, manufactures, and commercializes therapeutics. Its therapeutic drugs and medical services are streamlined to treat different types of cancer and enhance longevity. Its solutions treat a range of cancers like breast, bladder, Kaposi's sarcoma, lung, lymphoma, and ovarian, among others. The company leverages its experienced multi-scope team of executives to identify, negotiate and amalgamate top-notch research, technologies, therapeutics, and synergetic mechanisms to create value, slash costs, and propel the frequency of regulatory approval of safe and effective cancer drugs. Oncology Pharma was founded in March 1993 by Marcel van Heesewijk. Its shares are listed for trading on OTCPK under the ONPH ticker symbol. The company is headquartered in San Francisco, California.

Summary Corporate Business

The company focuses on integrating oncology with tech to enhance the fight against cancer. Over the years, the company has established several license agreements with top institutions that have developed unique technologies and mechanisms to aid in the transformation of the current oncology treatment landscape. The company is dedicated to hastening regulatory approval, improving the delivery system of cancer-fighting solutions, and developing cancer treatment mechanisms with decreased toxicity, while bettering technologies employed by doctors, researchers, and patients.

Oncology Pharma’s portfolio incorporates:

• Nanosmart Pharmaceuticals
• Connect2Med. A social engagement and retention platform used for clinical trials
• Sybleu, Inc. Offers cancer therapy through intratumoral injection of a chemotherapeutic agent accompanied by a bioactive immunostimulatory agent
• Regen. Advances Small Molecule Check Point NR2F6 and Antigen-Specific mRNA Cellular Cancer Vaccines services

Science and Tech

NanoSmart Pharmaceuticals (Licensed - LOI)

The company owns a premium drug delivery system capable of reaching numerous types of cancer cells and disorders. NanoSmart’s platform technology is a patented, human-derived, antinuclear antibody (ANA) that aims for narcosis presence areas in solid tumors. A cancer drug is encapsulated on a lipid nanoparticle and coated with NanoSmart’s antinuclear antibody. The resulting drug formulation is then intravenously administered into a patient’s bloodstream and smoothly travels to the tumor site. The encapsulation protects healthy tissues and organs from side effects, while ANA directly delivers loaded nanoparticles to necrotic tissues within tumor sites. Once embedded, the nanoparticle gradually discharges the cancer drug safely and efficiently.

Licensing Activities

Oncology Pharma formularized and entered a licensing agreement with NanoSmart for its unique patented drug delivery technology to help discharge its cancer drugs to various cancer tissues and organs, including the breast, bladder, liver, ovaries, etcetera.

The company inked a licensing agreement with Connect2Med for the latter’s smartphone App. Smartphones and their applications play a huge role in consumer healthcare transformation. The company uses the app to enroll, sign up, and support affected persons for clinical trials.

Oncology Pharma has licensed Small molecule modulators of NR2F6 Activity from KCL Therapeutics, Inc. These treat colon cancer in humans. The IP incorporates vital compounds for the alteration of NR2F6 activity.

The company has also licensed Antigen-Specific mRNA Cellular Cancer Vaccine IP from Regen Biopharma, Inc. The IP is used to treat pancreatic cancer in humans. Oncology Pharma aims to transform the oncology treatment sector via these vital agreements.

Recent Company and Industry Developments

The company’s stock declined roughly -7.1% in December 2021 following a year-end slip in its portfolio and operations update. The company stepped up its efforts to become eligible for listing on the Capital Markets Tier of Nasdaq. The firm took up necessary steps to finalize its audit after retaining PCAOB-qualified auditors to deliver it to up-listing eligibility. Oncology Pharma also fastened its commitment efforts towards Ribeira Solutions to secure licensing on the Connect2Med patient engagement platform and retention technology from the latter.

Leadership

Management

The company keeps a diverse and experienced team with spread expertise in business, finance, and investments. The management team composes:

George Malesek, CEO

• Joined the company as interim CEO to lead the firm through its capitalization and financing efforts
• Brings more than 25 years of experience in the capital market, having led and participated in numerous public and private company financing
• He has worked in private equity, investment banking, and merchant banking and has served in senior positions in both public and private institutions

Chuck Wagner, Director - Chairman of the Board

• Boats vital relationships across many industries and drove the company to critical businesses development
• He also provides networking and business consultation services to Double Crown Resources, Inc., Baylor College of Medicine, and Town Cloud, Inc.
• Holds a bachelor’s degree in communications from the University of Colorado

Dimitri Theofilopolous, Esq, Legal Counsel

• In 2013, he co-founded Batu Biologics, where he served as the CEO and General Counsel
• A former attorney for Scripps Research Institute
• He gained extensive litigation experience practicing employment and healthcare law in Los Angeles
• Holds a J.D from USC School of Law and a degree in History from UCLA

Carlos Barnett, Stefan Gruenwald, Ph.D./MD, and Shawn Crouse are the company’s Independent Directors.

Related Legal Matters

Two California men were indicted as a result of their suspected involvement in a sophisticated securities fraud scheme claimed to have generated illicit profits amounting to over $150 million. The two were Joseph A. Padilla, 53, and Kevin C. Dills, 66. Joseph A. Padilla was charged with one count of conspiracy to commit securities fraud, one count of attempt to unlawfully produce an identification document, and two counts of securities fraud. Kevin C. Dills, on the other hand, was charged with one count of securities fraud and one count of conspiracy to commit securities fraud. The defendants were scheduled to appear for their court hearing in Boston on March 29, 2023. The two individuals, who have histories of being barred from the securities industry by the SEC, were alleged to have taken part in a lucrative pump-and-dump involving Oncology Pharma stocks between October 2020 and July 2022.